PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|April 29, 2012
PDA Upcoming Workshops Tackle QbD, Vaccines, TSE, Viruses and More
Author(s)Angie Drakulich
PDA is hosting a few interesting workshops in the coming weeks on key topics facing the industry.
Advertisement
PDA is hosting a few interesting workshops in the coming weeks on key topics facing the industry. PharmTech spoke to experts participating in the workshop plans and you can listen to the interview podcasts
The two events are: 1-PDA/FDA Virus and TSE Safety Conference (May 15-17, 2012, Bethesda, MD): Interview with Dayue Chen, a Research Advisor in Bioprocess Development at Eli Lilly and Company. The focus of the conference is on Proactive Approaches to Mitigate Virus & TSE Risk. 2-QbD and Vaccines: A PDA/FDA Workshop (May 14, Bethesda, MD): Interview with Sam Venugopal of Pricewaterhouse Coopers. The focus of the workshop is on Applying QbD Principles in Vaccine Development.
Chen and Venugopal discuss why these topics were selected, current challenges within these areas, and key questions to be addressed at the meetings.
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement